Version 3 2024-06-18, 03:26Version 3 2024-06-18, 03:26
Version 2 2024-06-03, 19:28Version 2 2024-06-03, 19:28
Version 1 2018-05-31, 20:23Version 1 2018-05-31, 20:23
journal contribution
posted on 2024-06-18, 03:26authored byIG Barbosa, GN Vaz, NP Rocha, R Machado-Vieira, MRD Ventura, RB Huguet, ME Bauer, Michael BerkMichael Berk, AL Teixeira
Objective: Patients with bipolar disorder (BD) exhibit peripheral low-grade inflammation. The aim of the current study was to investigate the involvement of hitherto unexplored components of the tumor necrosis factor (TNF) superfamily in BD. Methods: Eighty patients with type I BD and 50 healthy controls matched for age and gender were enrolled in this study. All subjects were assessed with the Mini-Plus to evaluate psychiatric comorbidities; the Young Mania Rating Scale and the Hamilton Depression Rating Scale to evaluate manic and depressive symptoms severity, respectively. TNF superfamily molecules (TNF, TNF-related weak inducer of apoptosis [TWEAK], TNF-related apoptosis-inducing ligand [TRAIL], soluble TNF receptor type 1 [sTNFR1], and soluble TNF receptor type 2 [sTNFR2]) levels were measured by ELISA. Results: Patients with BD, regardless of mood state, presented increased plasma levels of sTNFR1 and TWEAK in comparison with controls. Conclusion: These findings corroborate the view that TNF superfamily may play a role in BD pathophysiology.